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Abstract: Melatonin is an endogenous molecule involved in many pathophysiological 
processes. In addition to the control of circadian rhythms, its antioxidant and 
neuroprotective properties have been widely described. Thus far, different bivalent 
compounds composed by a melatonin molecule linked to another neuroprotective agent 
were synthesized and tested for their ability to block neurodegenerative processes  
in vitro and in vivo. To identify a novel class of potential neuroprotective compounds,  
we prepared a series of bivalent ligands, in which a prototypic melatonergic ligand is 
connected to an imidazole-based H3 receptor antagonist through a flexible linker. Four  
imidazolyl-alkyloxy-anilinoethylamide derivatives, characterized by linkers of different 
length, were synthesized and their binding affinity for human MT1, MT2 and H3 receptor 
subtypes was evaluated. Among the tested compounds, 14c and 14d, bearing a pentyl  
and a hexyl linker, respectively, were able to bind to all receptor subtypes at micromolar 
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concentrations and represent the first bivalent melatonergic/histaminergic ligands reported 
so far. These preliminary results, based on binding affinity evaluation, pave the way  
for the future development of new dual-acting compounds targeting both melatonin and 
histamine receptors, which could represent promising therapeutic agents for the treatment 
of neurodegenerative pathologies. 
Keywords: melatonin receptor; MT1; MT2; H3 antagonists; bivalent ligands 
 
1. Introduction 
Melatonin (1, Figure 1) is a tryptophan-derived hormone primarily secreted by the pineal gland 
according to a circadian rhythm, with peak concentrations at night. Most of the regulatory functions 
exerted by this hormone are mediated by two high-affinity G-protein-coupled receptors, named MT1 
and MT2 [1], which are mainly expressed in the central nervous system (CNS) but are also present in 
different peripheral organs [2,3]. Nonetheless, melatonin has shown to bind also to several other 
cellular targets, including the MT3 binding site (quinone reductase 2), calmodulin, calreticulin, and 
tubulin [4], which could have a role in those phenotypic effects of melatonin that are independent of 
the activation of membrane-bound receptors. Additionally, melatonin effects could be also sustained 
by its metabolites, since it is rapidly transformed in the peripheral sites [5]. In addition to its  
well-established function in the regulation of the sleep-wake cycle and in the entrainment of circadian 
rhythms [6], melatonin is involved in a variety of other pathophysiological processes, including radical 
scavenging, attenuation of oxidative damage and neuroprotection [7–10]. Experimental evidence 
highlights the important role played by the activation of MT1 and MT2 receptors in sustaining its 
antioxidant and neuroprotective actions [11–14]. Even if the mechanism at the basis of this 
neuroprotective effect has not been completely elucidated, it is probably related to a multifactorial 
action exerted within the cell. For example, in motoneurons melatonin attenuated the production of 
reactive oxygen species, modulated Ca2+ levels and inhibited proapoptotic signaling [11,12]. In this 
context, not only melatonin but also synthetic compounds, like 2-iodomelatonin or other non-indole 
melatonergic ligands, have shown to efficiently produce antioxidant and cytoprotective effects and to 
block neurodegenerative processes both in vitro and in vivo [15,16]. Recently, different series of  
dual-acting compounds, constituted by melatonin linked to another known neuroprotective agent, have 
been reported as novel potential therapeutic agents for the treatment of neurodegenerative disorders. 
Indeed, hybrid melatonin-tacrine compounds showed potent anticholinesterase and antioxidant activity 
and melatonin-N,N-dibenzyl(N-methyl)amine hybrids also showed neuroprotective effects and were 
proposed as new potential therapeutic agents for neurodegenerative pathologies such as Parkinson’s 
and Alzheimer’s diseases. [17,18] Curcumin-melatonin hybrids showed antioxidant and neuroprotective 
actions as well, as demonstrated in in vitro studies on a cellular model of Alzheimer’s disease [19]. 
Histamine H3 receptors are mainly expressed in the CNS, with a predominantly presynaptic 
localization. They have been characterized as both autoreceptors and heteroreceptors, exerting a 
negative feedback mechanism on the synthesis and release of histamine and on the release of other 
neurotransmitters, such as acetylcholine, noradrenaline, dopamine, serotonin, etc. [20]. Histamine H3 
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receptor antagonists, which increase the release of such neurotransmitters, have been extensively 
investigated for the treatment of different CNS pathologies, such as narcolepsy, attention deficit 
hyperactivity disorder, obesity, and Alzheimer’s disease [21,22] and a number of potent and selective 
compounds are currently undergoing clinical trials. H3-antagonists have been also investigated for their 
neuroprotective potential and the improvement of cognitive disorders [23]. Several experimental 
studies evaluated the neuroprotective effects of different classes of H3 receptor antagonists in vitro and 
in vivo [24–26], highlighting their potential usefulness in the treatment of cognitive pathologies. 
Indeed, pretreatment with the H3 receptor antagonist ABT-239 was able to significantly attenuate 
kainic acid-mediated behavioral and excitotoxic effects [27]. Recently, a new class of compounds has 
been reported in which the pharmacophore for H3 receptor antagonists was combined with a  
3-indolyl-alkyl portion. These compounds exhibited potent H3 receptor antagonist activity and free 
radical scavenging properties and were hypothesized to be superior agents for Alzheimer’s disease 
therapy by acting in a complementary manner [28]. 
Figure 1. Structures of melatonin and of MT1-selective compounds bearing an  
aryl-alkyloxy chain.  
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Given the promising neuroprotective effects shown by melatonin receptor agonists and H3 receptor 
antagonists, we combined the pharmacophore elements of these classes into a single molecule, with the 
aim to retain the ability to bind both receptor subtypes. Structure-activity relationships (SARs) for 
melatonin receptor ligands showed that the introduction of an aryl-alkyloxy chain of suitable length in 
a position corresponding to that of the 5-methoxy group of melatonin is tolerated and leads to potent 
compounds selective for the MT1 subtype (e.g., compounds 2–4, Figure 1) [29–31]. According to the 
results of docking studies on a homology model of the MT1 receptor, it has been hypothesized that the 
substituent conferring subtype selectivity can be accommodated within a lipophilic channel, exposed to 
the solvent at its cytosolic terminus, which is available in the MT1 receptor. In the MT2 receptor  
this channel is much more crowded, given the presence of bulkier amino acids hampering the 
accommodation of the aryl-alkyloxy chain in the same manner as in the MT1 receptor [31].  
The classical pharmacophore model for H3 receptor antagonists is composed by three main 
portions, i.e., a basic group, a central lipophilic core usually connected through an alkyl spacer and a 
terminal group, which displays high chemical diversity as it could be a polar group, a lipophilic group 
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or another basic center [32]. The first H3 receptor antagonists were imidazole derivatives, while the 
second generation of compounds carried a different basic group, usually a piperidine or a pyrrolidine. 
Several series of potent imidazole-based H3 antagonists lacking a second basic center have been 
reported [33]. A polar atom/group is often present in these compounds, such as a thiourea  
(compound 5, Figure 2), a sulfonamide, or an oxygen atom (compounds 6 and 7). Good antagonists 
were also obtained with the insertion of a lipophilic chain only (compound 8), indicating that the 
presence of the imidazole ring is sufficient to preserve binding to the H3 receptor [34]. In addition, 
SARs for these non-basic imidazole-based H3 antagonists showed that the length of the alkyl linker can 
be significantly increased, sometimes reaching 9–10 methylene units, while maintaining significant H3 
binding affinity [35–38].  
Figure 2. Structures of imidazole-based H3 antagonists.  
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The possibility of obtaining high H3 receptor binding affinity for compounds lacking a strongly 
basic center is an important point in light of the merging of the pharmacophore elements of  
H3-antagonists with those of melatonergic agonists. In fact, introduction of basic groups on the 
scaffold of melatonergic ligands invariably brought to a loss of binding affinity [39,40]. On the other 
hand, the tolerance shown by the H3 receptor for the length of the alkyl spacer supports the possibility 
of combining H3 receptor and melatonin receptor pharmacophore elements through a suitable alkyl 
spacer. In fact, good MT1 binding affinities could be obtained with aryl-alkyloxy substituents having 
alkyl chains of four methylene units or longer. 
The melatonergic pharmacophore was provided by an anilinoethylamide fragment which already 
proved to bioisosterically reproduce the indol-3-ylethylamide portion of melatonin, affording 
compounds with similar binding affinity and intrinsic activity [41].Indeed, being the anilinoethylamide 
smaller than the indol-3-ylethylamide of melatonin, it could be better tolerated at the H3 receptor 
binding site. The anilinoethylamide fragment was decorated with an aryl-alkyloxy substituent 
containing the elements necessary for molecular recognition at the H3 receptor. The aryl-alkyloxy 
chain was a 4(5)-imidazolyl-alkyloxy one, seen in ciproxifan (7) and its analogs [42] (Figure 3). 
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Figure 3. Schematic representation of the strategy followed in the design of dual 
melatonergic-H3 receptor ligands.  
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Docking studies suggested that these compounds could be accommodated within the MT1 receptor 
binding site. The 4(5)-imidazolyl-alkyl portion could occupy the lipophilic pocket delimited by 
transmembrane (TM) helices 3, 4, and 5, with the terminal imidazole ring positioned at the rim of the 
TM portion of the receptor, where it could undertake polar interactions with amino acids in helices or 
extracellular loops (Figure 4, left). 
The H3 receptor should be able to interact with these compounds by binding their imidazole  
ring through E206 on TM5, as supported by mutagenesis experiments on histamine and other  
imidazole-based ligands [43]. The anilinoethylamide fragment could be docked within a lipophilic 
cavity identified in H3 receptor models [44,45], mainly delimited by TM2, 6 and 7, and roughly 
perpendicular to the region where E206 is located (Figure 4, right). The existence of this lipophilic 
cavity is supported by the high binding affinity shown by H3 receptor antagonists with two basic 
centers and a lipophilic substituent that could extend over both binding site cavities (Figure 5) [45–47]. 
Figure 4. (Left) hypothetical binding conformation of compound 14d (green carbons) 
within an MT1 receptor model (light gray carbons) [31]. Transmembrane helices 3, 5, 6 and 
7 are colored red, green, blue and yellow, respectively, while extracellular loop 2 is 
depicted in orange; (Right) hypothetical binding conformation of 14d within an H3 
receptor model (light gray carbons) [45]. Transmembrane helices 3, 5, 6 and 7 are colored 
red, green, blue and yellow, respectively, while extracellular loop 2 is depicted in orange. 
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Figure 5. Dibasic H3 receptor antagonists carrying a lipophilic substituent. 
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We report here the synthesis and evaluation of the binding affinity for histamine H3 and melatonin 
MT1 and MT2 receptors of four 3-(4(5)-imidazolyl-alkyloxy)-anilinoethylacetamides in which alkyl 
spacers of different length were introduced at position 3 of the aniline core, looking for an optimal 
linker to combine the H3 receptor- and the melatonin receptor-binding moieties.  
2. Results and Discussion 
2.1. Chemistry 
The synthesis of the dual melatonergic/histaminergic ligands is described in Schemes 1 and 2.  
The key starting alcohols 11a, 11c–d were prepared from the suitable aldehydes 8a, 8c–d  
following the previously reported three-step sequence (Wittig reaction, hydrogenation, LiAlH4 ester 
reduction) [48], whereas the alcohol 11b could be obtained by direct reduction of the aldehyde 8d [48] 
(Scheme 1). 
The N-protected compounds 13a–d were obtained by mesylation of the suitable (1-trityl-imidazol-
4-yl)alkan-1-ol 11a–d, followed by substitution of the intermediate methansulfonates 12a–d with  
N-{2-[(3-hydroxyphenyl)methylamino]ethyl}acetamide [31] in the presence of NaH. Deprotection of 
the imidazole ring under acidic conditions finally yielded the target compounds 14a–d (Scheme 2). 
Scheme 1. Synthesis of compounds 11a–d. a  
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a Reagents and conditions: (a) NaH, triethyl phosphonoacetate, THF, r.t.; (b) H2 (1 atm), 10% Pd/C, 
MeOH, 4 h, r.t.; (c) LiAlH4, THF, 4 h, reflux. 
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Scheme 2. Synthesis of compounds 14a–d. a  
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a Reagents and conditions: (a) mesyl chloride, TEA, CH2Cl2, 1 h, 0 °C; (b) NaH, DMF, 16 h, r.t.; 
(c) 2N HCl, THF, 3 h, 70 °C. 
2.2. Binding Affinities of Compounds 14a–d for Melatonin MT1, MT2 and Histamine H3 Receptors 
Binding affinities at human MT1, MT2 and H3 receptors of the newly synthesized  
N-(4(5)-imidazolyl-alkyloxy-anilinoethyl)acetamides 14a–d were assessed as described in the 
Experimental Section and are reported in Table 1.  
Table 1. Binding affinities (pKi) and intrinsic activities (IAR) measured for compounds 
14a–d at the human MT1, MT2 and H3 receptors. N.A. = Not active up to 100 μM.  
N.D. = Not determined.  
O N CH3
NHAc
N
HN
( )
n
Compound n hMT1 hMT2 hH3 
  pKi IAR pKi IAR pKi 
1  9.60 ± 0.18 1.00 ± 0.09 9.44 ± 0.12 1.00 ± 0.07 N.D. 
5  N.D. N.D. N.D. N.D. 7.28 ± 0.15 
14a 0 N.A.  N.A.  5.91 ± 0.01 
14b 1 N.A.  N.A.  N.D. 
14c 2 6.09 ± 0.12 N.D. 6.28 ± 0.10 N.D. 6.28 ± 0.03 
14d 3 6.79 ± 0.01 −0.26 ± 0.09 6.76 ± 0.06 −0.35 ± 0.19 6.22 ± 0.09 
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The bivalent melatonergic/histaminergic ligands differ for the length of the alkyl chain connecting 
the imidazole ring to the anilinoethylamide portion, spanning from three to six methylene units. 
Indeed, while for imidazole-based histamine H3 receptor ligands an ethyl or a propyl chain is usually 
preferred, for melatonergic ligands the optimal chain length is four methylene units or longer. 
Compound 14a with the shortest spacer was totally inactive towards both MT1 and MT2 melatonin 
receptors, whereas it showed micromolar affinity for the H3 receptor. Elongation of the alkyl chain 
with a fourth methylene unit (14b) was not sufficient to achieve binding affinity towards melatonin 
receptors The first active bivalent ligand was obtained with a pentyl linker connecting the imidazole 
ring to the melatonergic fragment (14c). Indeed, although compound 14c is significantly less potent 
than melatonin towards MT1 and MT2 receptors, it is able to bind to both melatonin and H3 receptor 
subtypes with micromolar affinity. A further elongation of the linker yielded the second active 
derivative 14d, with improved binding affinity for melatonin receptors compared to 14c. When 
evaluated in the GTPγS assay, 14c behaved as an antagonist at both MT1 and MT2 receptors.  
The low affinities of these compounds for melatonin receptors are likely to be ascribed to the 
presence of the imidazole ring. Indeed, compound 3 (Figure 1) displayed pKi = 8.93 for MT1 receptors 
and, more generally, in the series of phenyl-alkyloxy-anilinoethylamides alkyl chains longer than four 
methylene units provided compounds with good binding affinities [31]. According to our docking 
hypothesis, the partial recovery of binding affinity observed with longer spacers could be due to the 
accommodation of the imidazole ring into a more peripheral, solvent-exposed region of the receptor. 
The limited binding affinity might be related to the presence, in this area, of some positively-charged 
amino acids belonging to extracellular loop 2 (e.g., R164 and R173 in the MT1 receptor) which could 
negatively interact with the imidazole ring (Figure 4). The presence of the imidazole ring is likely 
related to the antagonist behavior shown by 14d. It remains to be evaluated if replacement of this ring 
with other heterocycles, tolerated by the H3 receptor, could restore the agonist activity. 
Alkyl chain length seems not to significantly influence binding affinity at the H3 receptor. The longest 
derivatives 14c–d are those with highest binding affinities, about 10 times lower than the reference 
imidazole-based H3 antagonist thioperamide (5). We may speculate that the anilinoethylamide portion 
undertakes some unfavorable interaction with the binding site which could contribute to the limited 
binding affinity observed for these compounds. 
3. Experimental Section  
3.1. General Experimental Procedures 
1H NMR (200 MHz) and 13C NMR (50 MHz) spectra were recorded on a Bruker (Billerica, MA, 
USA) AVANCE 200 spectrometer, using CDCl3 as solvent. Chemical shifts (δ scale) are reported in 
parts per million (ppm) relative to the central peak of the solvent. Coupling constants (J values) are 
given in hertz (Hz). ESI-MS spectra were taken on a Waters (Milford, MA, USA) Micromass Zq 
instrument. Elemental analyses for C, H and N were performed on a Carlo Erba (Milan, Italy) 
analyzer, and the results are within 0.4% of the calculated values. UV-Vis spectra were recorded using 
a Beckman (Brea, CA, USA) DU640 spectrophotometer. Column chromatography purifications were 
performed under “flash” conditions using Merck 230–400 mesh silica gel. Analytical thin-layer 
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chromatography (TLC) was carried out on Merck (Darmstadt, Germany) silica gel 60 F254  
plates. Reagents were obtained from commercial suppliers and used without further  
purification. The aldehyde 8a was commercially available; aldheydes 8c–d [48] and  
N-{2-[(3-hydroxyphenyl)methylamino]ethyl}acetamide [31] were prepared as previously reported. 
The two radioligands 2-[125I]iodomelatonin (specific activity, 2000 Ci/mMol) and [35S]GTPγS 
([35S]guanosine-5'-O-(3-thio-triphosphate); specific activity, 1000 Ci/mMol) were purchased from 
PerkinElmer (Waltham, MA, USA). [3H](R)-α-methylhistamine (specific activity, 47.0 Ci/mMol) was 
purchased from Amersham Bioscience (Amersham, UK). 
3.2. Synthetic Procedures 
3.2.1. Synthesis of Unsaturated Esters 9a, 9c–d  
General Procedure: A solution of triethyl phosphonoacetate (0.2 mL, 1 mMol) in THF (6 mL) was 
added to an ice-cooled suspension of NaH (80% dispersed in mineral oil, 0.030 g, 1 mMol) in THF  
(6 mL) and the resulting mixture was stirred at room temperature for 30 min. A solution of the 
opportune aldehyde 8a, 8c–d [48] (0.9 mMol) in THF (6 mL) was added dropwise and the mixture  
was stirred for 16 h at room temperature. The reaction mixture was then poured into iced water and 
extracted 3× with diethyl ether; the organic phases were combined, dried (Na2SO4) and concentrated to 
give a crude residue which was purified by flash chromatography (silica gel, EtOAc as eluent). 
3.2.2. (E)-Ethyl 3-(1-trityl-1H-imidazol-4-yl)acrylate (9a)  
The chemical physical data are identical to those reported in literature [49]. 
3.2.3. (E)-Ethyl 5-(1-trityl-1H-imidazol-4-yl)pent-2-enoate (9c)  
ESI MS (m/z): 437 (M + 1)+; 243 (Ph3C+). The chemical physical data are identical to those 
reported in literature [48]. 
3.2.4. (E)-Ethyl 6-(1-trityl-1H-imidazol-4-yl)hex-2-enoate (9d)  
Oil; 46% yield. ESI MS (m/z): 451 (M + 1)+; 243 (Ph3C+). 1H NMR (CDCl3): δ 1.29 (t, 3H J = 7.0), 
1.76–1.88 (m, 2H), 2.17–2.24 (m, 2H), 2.54–2.61 (m, 2H), 4.18 (q, 2H J = 7.0), 5.78 (d, 1H, J = 16.0), 
6.53 (s, 1H), 6.89–7.04 (dt, 1H, J = 7.0 and 16.0), 7.12–7.36 (m, 16H). 
3.2.5. Synthesis of Ester Derivatives 10a, 10c–d  
General Procedure: A solution of the suitable ethyl ester 9a, 9c–d (1 mMol) in MeOH (5 mL) was 
hydrogenated under hydrogen atmosphere in the presence of 10% Pd/C (40 mg) for 4 h at room 
temperature. The catalyst was removed by filtration on Celite, and the filtrate was concentrated under 
reduced pressure to afford a crude residue which was purified by flash chromatography (silica gel, 
EtOAc as eluent).  
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3.2.6. Ethyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (10a)  
White solid; 84% yield. ESI MS (m/z): 411 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.24 (t, 3H,  
J = 7.0), 2.12 (t, 2H, J = 7.5), 2.64 (t, 2H, J = 7.5), 4.15 (q, 2H, J = 7.0), 6.63 (s, 1H), 7.14–7.39 (m, 16H). 
3.2.7. Ethyl 5-(1-trityl-1H-imidazol-4-yl)pentanoate (10c)  
ESI MS (m/z): 439 (M + 1)+; 243 (Ph3C+). The chemical physical data are identical to those 
reported in literature [48]. 
3.2.8. Ethyl 6-(1-trityl-1H-imidazol-4-yl)hexanoate (10d)  
Oil; 86% yield. ESI MS (m/z): 453 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.25 (t, 3H J = 7.0), 
1.25–1.42 (m, 2H), 1.57–1.72 (m, 4H), 2.25–2.32 (m, 2H), 2.51–2.59 (m, 2H), 4.12 (q, 2H J = 7.0), 
6.53 (s, 1H), 7.12–7.38 (m, 16H). 
3.2.9. Synthesis of Alcohol Derivatives 11a, 11c–d  
General Procedure: A solution of appropriate ester 10a, 10c–d (1 mMol) in dry THF (4 mL) was 
added dropwise to a suspension of LiAlH4 (0.076 g, 2 mMol) in dry THF (4 mL) and the resulting 
mixture was refluxed for 4 h. After cooling to 0 °C the reaction mixture was quenched by slow 
addition of a saturated aqueous solution of NaHCO3 and EtOAc. The mixture was filtered on Celite, 
the filtrate was concentrated under reduced pressure to afford a residue which was taken up in CH2Cl2 
and washed with a saturated aqueous solution of NaHCO3. The organic phase was dried (Na2SO4) and 
concentrated in vacuo to give a crude product which was purified by flash chromatography (silica gel, 
EtOAc to EtOAc/MeOH 97/3 as eluent). 
3.2.10. 3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol (11a)  
ESI MS (m/z): 369 (M + 1)+; 243 (Ph3C+). The chemical physical data are identical to those 
reported in literature [48]. 
3.2.11. 4-(1-Trityl-1H-imidazol-4-yl)butan-1-ol (11b)  
The product was obtained by direct reduction of the aldehyde 8d as previously reported and the 
chemical physical data are identical to those reported in literature [48]. ESI MS (m/z): 383 (M + 1)+; 
243 (Ph3C+). 
3.2.12. 5-(1-Trityl-1H-imidazol-4-yl)pentan-1-ol (11c)  
ESI MS (m/z): 397 (M + 1)+; 243 (Ph3C+). The chemical physical data are identical to those 
reported in literature [48]. 
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3.2.13. 6-(1-Trityl-1H-imidazol-4-yl)hexan-1-ol (11d)  
Oil; 94% yield. ESI MS (m/z): 411 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.23–1.39 (m, 4H), 
1.48–1.67 (m, 4H), 2.52–2.60 (m, 2H), 3.59–3.65 (m, 2H), 6.52 (s, 1H), 7.09–7.40 (m, 16H). 
3.2.14. Synthesis of Mesyl Derivatives 12a–d  
General Procedure: Methanesulfonyl chloride (0.25 g, 2.2 mMol) was added to an ice-cooled 
solution of the opportune alcohol 11a–d (1.8 mMol) in dry CH2Cl2 (8 mL) and TEA (0.24 g,  
2.4 mMol). The reaction mixture was stirred under nitrogen atmosphere at 0 °C for 1 h (for 10a further 
3 h at room temperature), quenched with water and washed once with an aqueous solution of  
5% NaHCO3. The organic phase was dried over Na2SO4 and the solvent removed by distillation to 
afford the crude mesylate (12a–d), which was used in the next step without any further purification. 
3.2.15. 3-(1-Trityl-1H-imidazol-4-yl)propyl methansulfonate (12a)  
Oil; 92% yield. ESI MS (m/z): 447 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 2.11 (quint, 2H), 
2.65–2.77 (m, 2H), 2.97 (s, 3H), 4.26 (t, 2H), 6.59 (s, 1H), 7.12–7.44 (m, 16H).  
3.2.16. 4-(1-Trityl-1H-imidazol-4-yl)butyl methansulfonate (12b)  
Oil; 95% yield. ESI MS (m/z): 461 (M + 1)+, 243 (Ph3C+). 
3.2.17. 5-(1-Trityl-1H-imidazol-4-yl)pentyl methansulfonate (12c)  
Oil; 87% yield. ESI MS (m/z): 475 (M + 1)+, 243 (Ph3C+). 
3.2.18. 6-(1-Trityl-1H-imidazol-4-yl)hexyl methansulfonate (12d)  
Oil; 88% yield. ESI MS (m/z): 489 (M + 1)+, 243 (Ph3C+). 
3.2.19. Synthesis of Derivatives 13a–d  
General Procedure: NaH (80% in mineral oil, 0.036 g, 1.2 mMol) was added to a solution of  
N-{2-[(3-hydroxyphenyl)methylamino]ethyl}acetamide [31] (0.21 g, 1 mMol) in dry DMF (2.2 mL) 
under nitrogen atmosphere. After stirring for 30 min at room temperature, a solution of the suitable 
mesyl derivative 12a–d (1 mMol) in dry DMF (1 mL) was added to the reaction mixture and stirring 
continued for 16 h. The reaction mixture was poured into water and extracted 3× with EtOAc. The 
organic phases were combined, washed once with brine, dried (Na2SO4) and concentrated to give a 
crude residue, which was purified by flash chromatography (silica gel, EtOAc as eluent). 
3.2.20. N-[2-(Methyl{3-[3-(1-trityl-1H-imidazol-4-yl)propoxy]phenyl}amino)ethyl]acetamide (13a) 
Oil; 67% yield. ESI MS (m/z): 559 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.92 (s, 3H),  
2.06-2.18 (m, 2H), 2.74 (t, 2H, J = 7.5), 2.93 (s, 3H), 3.45 (m, 4H), 3.98 (t, 2H, J = 6.5), 5.86 (brs, 1H), 
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6.25 (dd, 1H, J = 2.0 and 8.0), 6.27 (m, 1H), 6.36 (dd, 1H, J = 2.0 and 8.0), 6.58 (s, 1H), 7.08–7.38  
(m, 17H). 
3.2.21. N-[2-(Methyl{3-[4-(1-trityl-1H-imidazol-4-yl)butoxy]phenyl}amino)ethyl]acetamide (13b)  
Oil; 40% yield. ESI MS (m/z): 573 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.67–1.78 (m, 4H), 
1.91 (s, 3H), 2.75 (t, 2H), 2.94 (s, 3H), 3.48 (m, 4H), 4.00 (t, 2H), 5.82 (brs, 1H), 6.26 (dd, 1H, J = 2.0 
and 8.0), 6.29 (m, 1H), 6.38 (dd, 1H, J = 2.0 and 8.0), 6.59 (s, 1H), 7.06–7.41 (m, 17H). 13C NMR 
(CDCl3): δ 170.4, 160.3, 150.8, 142.3, 141.1, 138.0, 129.9, 129.7, 128.0, 117.9, 105.4, 102.4, 99.7, 
75.3, 67.6, 51.7, 38.4, 37.2, 29.7, 28.9, 27.9 25.8, 23.2. 
3.2.22. N-[2-(Methyl{3-[5-(1-trityl-1H-imidazol-4-yl)pentyloxy]phenyl}amino)ethyl]acetamide (13c)  
Oil; 71% yield. ESI MS (m/z): 587 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.44–1.55 (m, 2H), 
1.62–1.82 (m, 4H), 1.91 (s, 3H), 2.57 (t, 2H J = 7.5), 2.92 (s, 3H), 3.41–3.44 (m, 4H), 3.93 (t, 2H  
J = 6.5), 5.96 (brs, 1H), 6.25 (dd, 1H, J = 2.0 and 8.0), 6.27 (m, 1H), 6.36 (dd, 1H, J = 2.0 and 8.0), 
6.54 (s, 1H), 7.10–7.36 (m, 17H). 13NMR (CDCl3): δ 170.4, 160.4, 150.8, 142.5, 141.7, 138.2, 129.9, 
129.8, 128.0, 117.8, 105.4, 102.3, 99.7, 75.1, 67.8, 51.7, 38.4, 37.3, 29.5, 29.2, 29.1, 28.3, 25.8, 23.2. 
3.2.23. N-[2-(Methyl{3-[6-(1-trityl-1H-imidazol-4-yl)hexyloxy]phenyl}amino)ethyl]acetamide (13d)  
Oil; 85% yield. ESI MS (m/z): 601 (M + 1)+, 243 (Ph3C+). 1H NMR (CDCl3): δ 1.26–1.52 (m, 4H), 
1.53–1.75 (m, 4H), 1.95 (s, 3H), 2.60 (t, 2H J = 7.5), 2.94 (s, 3H), 3.45–3.47 (m, 4H), 3.94 (t, 2H  
J = 6.5), 5.75 (brs, 1H), 6.27 (dd, 1H, J = 2.0 and 8.0), 6.29 (m, 1H), 6.37 (dd, 1H, J = 2.0 and 8.0), 
6.57 (s, 1H), 7.13–7.35 (m, 17H). 
3.2.24. Synthesis of Target Derivatives 14a–d  
General Procedure: A solution of the suitable trityl derivative 13a–d (0.5 mMol) and 2 N HCl  
(2 mL) in THF (1 mL) was heated at 70 °C for 3 h. The reaction mixture was washed with diethyl 
ether, the aqueous phase basified with 2 N Na2CO3 and extracted 3× with diethyl ether. The organic 
phases were combined, dried (Na2SO4) and concentrated to give a residue that was purified by 
filtration through a silica gel plug (EtOAc-MeOH 85:15 as eluent). 
3.2.25. N-[2-({3-[3-(1H-Imidazol-4-yl)propoxy]phenyl}methylamino)ethyl]acetamide (14a)  
Oil; 57% yield. ESI MS (m/z): 317 (M + 1)+. 1H NMR (CDCl3): δ 1.96 (s, 3H), 2.06–2.15 (m, 2H), 
2.83 (t, 1H, J = 7.0), 2.94 (s, 3H), 3.45 (m, 4H), 4.03 (t, 1H, J = 6.5), 6.10 (brs, 1H), 6.26–6.37  
(m, 3H), 6.83 (s, 1H), 7.13 (dd, 1H, J1 = J2 = 8.0), 7.60 (s, 1H). 13C NMR (CDCl3): δ 170.9, 160.2, 
150.7, 135.6, 134.5, 130.0, 118.3, 105.3, 102.6, 99.3, 67.0, 51.6, 38.4, 37.1, 29.7, 29.3, 23.2. UV-Vis 
(MeOH) λ = 253 (12,600), 293 (4300) nm (ε). Anal. calcd for C17H24N4O2: C 64.53, H 7.65, N 17.71, 
found: C 64.29, H 7.70, N 17.39. 
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3.2.26. N-[2-({3-[4-(1H-Imidazol-4-yl)butoxy]phenyl}methylamino)ethyl]acetamide (14b)  
Oil; 66% yield. ESI MS (m/z): 331 (M + 1)+. 1H NMR (CDCl3): δ 1.86–1.90 (m, 2H), 1.99 (s, 3H), 
2.75–2.82 (m, 4H), 2.95 (s, 3H), 3.46 (m, 4H), 4.02 (t, 2H J = 6.5), 6.24 (brs, 1H), 6.26–6.41 (m, 3H), 
6.97 (s, 1H), 7.13 (dd, 1H, J1 = J2 = 8.0), 7.93 (s, 1H). 13C NMR (CDCl3): δ 170.9, 160.2, 150.7, 
136.3, 133.6, 130.0, 117.5, 105.4, 102.4, 99.7, 67.5, 51.7, 38.4, 37.1, 28.5, 25.9, 25.7, 23.2. Anal. calcd 
for C18H26N4O2: C 65.43, H 7.93, N 16.96, found: C 65.18, H 8.01, N 16.60. 
3.2.27. N-[2-({3-[5-(1H-Imidazol-4-yl)pentyloxy]phenyl}methylamino)ethyl]acetamide (14c)  
Oil; 92% yield. ESI MS (m/z): 345 (M + 1)+. 1H NMR (CDCl3): δ 1.43–1.56 (m, 2H), 1.60–1.84 (m, 
4H), 1.95 (s, 3H), 2.67 (t, 2H J = 7.0), 2.94 (s, 3H), 3.45–3.47 (m, 4H), 3.96 (t, 2H J = 6.5), 6.05 (brs, 
1H), 6.25–6.37 (m, 3H), 6.81 (s, 1H), 7.13 (dd, 1H, J1 = J2 = 8.0), 7.61 (s, 1H). 13C NMR (CDCl3):  
δ 170.9, 160.2, 150.7, 136.1, 134.1, 129.9, 118.0, 105.3, 102.2, 99.5, 67.5, 51.6, 38.4, 37.2, 28.9, 28.9, 
26.2, 25.6, 23.2. UV-Vis (MeOH) λ = 253 (13,000), 293 (4100) nm (ε). Anal. calcd for C19H28N4O2:  
C 66.25, H 8.19, N 16.27, found: C 66.03, H 8.16, N 15.88. 
3.2.28. N-[2-({3-[6-(1H-Imidazol-4-yl)hexyloxy]phenyl}methylamino)ethyl]acetamide (14d)  
Oil; 84% yield. ESI MS (m/z): 359 (M + 1)+. 1H NMR (CDCl3): δ 1.41–1.47 (m, 4H), 1.61–1.80 (m, 
4H), 1.94 (s, 3H), 2.64 (t, 2H J = 7.0), 2.94 (s, 3H), 3.45–3.47 (m, 4H), 3.95 (t, 2H J = 6.5), 5.88 (brs, 
1H), 6.27–6.39 (m, 3H), 6.78 (s, 1H), 7.13 (dd, 1H, J1 = J2 = 8.0), 7.58 (s, 1H). 13C NMR (CDCl3): 
170.7, 160.3, 150.8, 136.3, 134.1, 129.9, 117.8, 105.3, 102.2, 99.6, 67.6, 51.7, 38.4, 37.3, 29.1, 29.1, 
28.7, 26.2, 25.7, 23.2. UV-Vis (MeOH) λ = 252 (13,200), 294 (4100) nm (ε). Anal. calcd for 
C20H30N4O2: C 67.01, H 8.44, N 15.63, found: C 66.70, H 8.42, N 15.33. 
3.3. Human Histamine H3 Receptor Binding Assay 
Homogenates of SK–N–MC cells expressing human histamine H3 receptors (hH3Rs) were used  
to determine affinity values of the new compounds in radioligand displacement studies according  
to Lovenberg et al.’s method [50]. SK–N–MC cells in confluent culture plates were harvested  
using trypsin digestion and then centrifuged for 5 min at 1100 rpm. Pellets, either fresh or stored at 
−80 °C until the moment of use, were mechanically homogenized with Potter-Elvhejem in 20 mM  
Tris-HCl/0.5 mM EDTA. Supernatants from a 2000 rpm spin (10 min) were collected and  
re-centrifuged at 10,000 rpm for 30 min. Pellets were re-homogenized in 50 mM Tris-HCl/5 mM 
EDTA (pH 7.4). Membranes were incubated for 60 min at room temperature with 0.5 nM  
[3H](R)-α-methylhistamine in 50 mM Tris-HCl/5 mM EDTA (pH 7.4) with or without competing 
ligands. Each concentration was tested in triplicate. Incubation was terminated by rapid filtration over 
Millipore (Darmstadt, Germany) AAWPO2500 filters followed by two washes with ice-cold buffer  
(50 mM Tris-HCl/5 mM EDTA). Filters retained radioactivity was determined by liquid scintillation 
counting (Ultima Gold XR Perkin Elmer (Waltham, MA, USA) scintillation liquid, Tri-Carb 2810 TR 
Perkin Elmer (Waltham, MA, USA) Liquid Scintillation Analyzer). Non-specific binding was defined 
with 10 μM histamine as competing ligand. pIC50 and Hill coefficient values were estimated from the 
displacement curves of the tested compounds (10 nM–100 μM) versus [3H](R)-α-methylhistamine, using 
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Prism (San Diego, CA, USA) GraphPad 2005, and converted into pKi values according to the  
Cheng–Prusoff equation [51]. Data are expressed as mean ± SEM of three independent experiments. 
3.4. Human Melatonin Receptors Binding Assay 
Binding affinities were determined using 2-[125I]iodomelatonin as the labeled ligand in competition 
experiments with cloned human MT1 and MT2 receptors expressed in NIH3T3 rat fibroblast cells. The 
characterization of NIH3T3 MT1 and MT2 cells was already described in detail [52,53]. Membranes 
were incubated for 90 min at 37 °C in binding buffer (50 mM Tris/HCl, pH 7.4). The final membrane 
concentration was 5–10 μg of protein per tube. The membrane protein level was determined in 
accordance with a previously reported method [54]. 2-[125I]Iodomelatonin (100 pM) and different 
concentrations of the tested compounds were incubated with the receptor preparation for 90 min at  
37 °C. Nonspecific binding was assessed with 10 μM melatonin; IC50 values were determined by 
nonlinear fitting strategies with Prism (GraphPad SoftWare Inc., San Diego, CA, USA). The pKi 
values were calculated from the IC50 values according to the Cheng–Prusoff equation [51]. The pKi 
values are the mean of at least three independent determinations performed in duplicate. 
To determine the functional activity of compound 14d at MT1 and MT2 receptor subtypes, 
[35S]GTPγS binding assays in NIH3T3 cells expressing human-cloned MT1 or MT2 receptors were 
performed. The amount of bound [35S]GTPγS is proportional to the level of the analog-induced G 
protein activation and is related to the intrinsic activity of the compound under study. The detailed 
description and validation of this method were reported elsewhere [52,55]. Membranes (15–25 μg of 
protein, final incubation volume 100 μL) were incubated at 30 °C for 30 min in the presence and 
absence 14d, in assay buffer consisting of [35S]GTPγS (0.3–0.5 nM), GDP (50 μM), NaCl (100 mM), 
and MgCl2 (3 mM). Nonspecific binding was defined using GTPγS (10 μM). In cell lines expressing 
human MT1 or MT2 receptors, melatonin produced concentration-dependent stimulation of basal 
[35S]GTPγS binding with a maximal stimulation above basal levels of 370% and 250% in MT1 and 
MT2 receptors, respectively. Basal stimulation is the amount of [35S]GTPγS specifically bound in the 
absence of compounds and was taken as 100%. The maximal G protein activation was measured in 
each experiment using melatonin (100 nM). Compounds were added at three different concentrations 
(one concentration equivalent to 100 nM melatonin, a second one, 10-fold smaller, and a third one,  
10-fold larger), and the percent stimulation above basal was determined. The equivalent concentration 
was estimated on the basis of the ratio of the affinity of the test compound to that of melatonin. It was 
assumed that, at the equivalent concentration, the test compound occupies the same number of 
receptors as 100 nM melatonin. All of the measurements were performed in triplicate. The relative 
intrinsic activity (IAR) values were obtained by dividing the maximum ligand induced stimulation of 
[35S]GTPγS binding by that of melatonin, as measured in the same experiment. 
3.5. Docking Studies 
All docking simulations were performed with Glide 5.7 [56]; Maestro 9.2 [57] was applied to 
prepare ligand structures and to refine protein-ligand complexes. 
  
Int. J. Mol. Sci. 2014, 15 16128 
 
 
3.5.1. MT1 Receptor  
A previously-reported MT1 receptor model [31] was taken as starting point for induced-fit docking 
(IFD) of compounds 14a–d. An initial softened-potential docking run was performed applying van der 
Waals radii scaling of 0.7 and 0.5 on protein and ligand non-polar atoms, respectively. Amino acids 
hampering the accommodation of the imidazole ring of 14a–d, i.e., Q101 and Q169, were temporarily 
mutated to alanines. Energy grids generated for the initial softened-potential docking were centered in 
the putative binding site of the receptor, setting enclosing and bounding boxes to default dimensions. 
During flexible docking runs, two hydrogen bond constraints were applied between Y187 hydroxyl 
group and the phenolic oxygen of the ligand, and between Y285 hydroxyl group and the amide oxygen 
of the ligand, to reproduce the main polar interactions previously proposed for melatonergic ligands. 
Ligand docking was performed in standard precision (SP) mode, collecting fifty poses. The resulting 
ligand–receptor complexes were then submitted to a protein structure refinement stage; once amino 
acid side chains that had previously been removed were re-introduced, residues within a shell of 5 Å 
around any ligand pose were refined by a side chain conformational search, followed by energy 
minimization of the residues and the ligand molecule. In the final docking stage, each ligand structure 
obtained at the end of the protein structure refinement was energetically optimized (refined) in the field 
of the receptor and subsequently scored using default Glide settings. The final ligand-protein 
complexes were ranked according to their IFD score, a composite score that accounts for  
ligand-receptor interaction energy, receptor strain and solvation terms. The best-ranked MT1-14a–d 
complexes were minimized applying the OPLS2005 force field [58] to a convergence threshold of  
0.05 kJ·mol−1·Å−1. During this minimization procedure, the ligand and residues within 8 Å from the 
ligand were free to move, while all other atoms were retained fixed. 
3.5.2. H3 Receptor  
A previously-reported model of the histamine H3 receptor [45] was used as reference structure for 
docking studies of compounds 14a–d. Glide grids were centered in the putative binding site of the 
receptor, located between D114 and E206, setting the dimension of enclosing and bounding boxes to 
default values. Compounds 14a–d were flexibly docked within the H3 receptor binding cavity in SP 
mode, applying a van der Waals radii scaling of 0.7 on ligand non-polar atoms. During docking runs,  
a hydrogen bond constraint was applied between E206 and the imidazole ring of the ligands. Fifty 
poses were collected for each ligand and ranked according to their Emodel value. The best-scored 
ligand conformations were merged into the H3 receptor model and the resulting complexes were 
minimized applying the OPLS2005 force field to an energy gradient of 0.05 kJ·mol−1 Å−1. During this 
minimization phase, the docked compound and all residues within 8 Å from the ligand were free to 
move, whereas all other atoms were retained fixed. 
4. Conclusions  
We reported the synthesis and binding affinity evaluation of a series of bivalent 
melatonergic/histaminergic ligands characterized by an imidazolyl-alkyloxy-anilinoethylamide 
structure. In this series, four derivatives with alkyl linkers of different length were tested for their 
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ability to bind human MT1, MT2 and H3 receptor subtypes. Among the tested compounds, 14c and 14d, 
bearing a pentyl and a hexyl linker between the imidazole ring and the aniline core, respectively, were  
able to bind to all receptor subtypes at micromolar concentrations. Although these two compounds  
might possess sub-optimal binding affinities, they are the first bivalent melatonergic/histaminergic ligands 
reported so far and might represent promising starting points for the development of potent dual-acting 
agents, potentially useful for the treatment of cognitive disorders. 
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